Iovance Biotherapeutics, Inc.IOVANASDAQ
Loading
R&D Expenses Over TimeStrong
Percentile Rank93
3Y CAGR+0.6%
5Y CAGR+8.3%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+0.6%/yr
vs +31.1%/yr prior
5Y CAGR
+8.3%/yr
Recent deceleration
Acceleration
-30.5pp
Decelerating
Percentile
P93
Near historical high
vs 5Y Ago
1.5x
Solid growth
Streak
1 yr
Consecutive growthStrong
PeriodValueYoY Change
TTM$300.27M+6.4%
2024$282.34M-17.9%
2023$344.08M+16.7%
2022$294.78M+13.8%
2021$259.04M+28.4%
2020$201.73M+21.5%
2019$166.02M+66.3%
2018$99.83M+39.4%
2017$71.61M+155.4%
2016$28.04M-